Compare DexCom, Inc. (DXCM) vs Jones Lang LaSalle Inc (JLL) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

JLL (Jones Lang LaSalle) stock trades at $330.31, up 5.06% on the day, showing strong momentum. The technical picture is bullish, with the price above key resistance levels. Fundamentally, the company has delivered three consecutive earnings beats, with revenue growing to $26.12B in 2025 and net income margin improving to 3.03%. Recent news highlights significant capital markets activity, including a $332M Chicago tower refinancing and a study suggesting AI will drive workforce growth, not cuts.

The outlook is positive, supported by analyst consensus for a 25% upside to a $405.50 price target and a 'Buy' rating from 55% of covering analysts. Key opportunities include continued execution in capital markets and property services, while risks involve exposure to commercial real estate cycles and potential macroeconomic headwinds affecting transaction volumes.